https://scholars.lib.ntu.edu.tw/handle/123456789/540783
標題: | Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study | 作者: | Lee M.-H. Yang H.-I. Lu S.-N. Jen C.-L. You S.-L. Wang L.-Y. Wang C.-H. WEI J. CHEN Chen C.-J. CHANG-YAO HSIEH Lee, Hsuan-Shu PEI-MING YANG CHIEN-HUNG CHEN Chen J.D. Huang S.P. CHYI-FENG JAN HSIU-HSI CHEN Sun C.A. Wu M.H. Chen S.Y. Chu K.E. Ho S.C. Lu T.G. Wu W.P. Ou T.Y. Lin C.G. Shih K.C. Chung W.S. Li C. Chen C.C. How W.C. |
公開日期: | 2012 | 卷: | 206 | 期: | 4 | 起(迄)頁: | 469-477 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. The study aimed to evaluate the risk of hepatitis C virus (HCV) infection on hepatic and extrahepatic deaths. Methods. A cohort of 23 820 adults aged 30-65 years old were enrolled during 1991-1992. The seromarkers hepatitis B surface antigen (HBsAg), anti-HCV, and serum HCV RNA levels at study entry were tested. The vital status was ascertained through computerized linkage with national death certification profiles from 1991 to 2008. Results. There were 19 636 HBsAg-seronegatives, including 18 541 anti-HCV seronegatives and 1095 anti- HCV seropositives. Among anti-HCV seropositives, 69.4% had detectable serum HCV RNA levels. There were 2394 deaths that occurred during an average follow-up period of 16.2 years. Compared with anti-HCV seronegatives, anti-HCV seropositives had higher mortality from both hepatic and extrahepatic diseases, showing multivariate- adjusted hazard ratio (95% confidence interval) of 1.89 (1.66-2.15) for all causes of death; 12.48 (9.34-16.66) for hepatic diseases; 1.35 (1.15-1.57) for extrahepatic diseases; 1.50 (1.10-2.03) for circulatory diseases; 2.77 (1.49-5.15) for nephritis, nephrotic syndrome, and nephrosis; 4.08 (1.38-12.08) for esophageal cancer; 4.19 (1.18- 14.94) for prostate cancer; and 8.22 (1.36-49.66) for thyroid cancer. Anti-HCV seropositives with detectable HCV RNA levels had significantly higher mortality from hepatic and extrahepatic diseases than anti-HCV seropositives with undetectable HCV RNA. Conclusions. Monitoring HCV RNA in anti-HCV seropositives is essential for the prediction of mortality associated with hepatitis C. ? The Author 2012. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866898184&doi=10.1093%2finfdis%2fjis385&partnerID=40&md5=3c64ed1f16f9394435848d8573888ce5 https://scholars.lib.ntu.edu.tw/handle/123456789/540783 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jis385 | SDG/關鍵字: | hepatitis B surface antigen; hepatitis C antibody; virus RNA; hepatitis C antibody; adult; aged; article; cancer mortality; cause of death; cohort analysis; controlled study; death certificate; esophagus cancer; female; hepatitis C; human; infection risk; ischemia; liver disease; major clinical study; male; mortality; nephritis; nephrosis; nephrotic syndrome; priority journal; prospective study; prostate cancer; thyroid cancer; blood; hepatitis C; longitudinal study; middle aged; mortality; risk assessment; Adult; Aged; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Risk Assessment; RNA, Viral |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。